Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COCENSYS PLANS MID-1992 IND FILING FOR "EPALON" EPILEPSY COMPOUND

Executive Summary

COCENSYS PLANS MID-1992 IND FILING FOR "EPALON" EPILEPSY COMPOUND to be followed by IND filings for the CNS start-up's "Epalon" compounds for anxiolytic and hypnotic indications. The biopharmaceutical R&D firm's lead compound is intended for the prevention of petit mal seizures and also may prove effective for the treatment of infantile spasms, the company said. CoCensys has characterized and isolated approximately 60 Epalon compounds derived from endogenous metabolites of progesterone. The compounds are said to be highly selective to gamma-aminobutyric (GABA) receptors and therefore have fewer side effects than traditional treatments for epilepsy, insomnia and anxiety, such as sedation and cognitive impairments. In preclinical testing, CoCensys' Epalons demonstrated fewer side effects than the current first-line therapy for petit mal epilepsy, Parke-Davis' Zarontin (ethosuximide), the company said. Epalon compounds are allosteric modulators, which work by enhancing the activity of the GABA inhibitory neurotransmitter to control over-active nerve responses, CoCensys explained. Benzodiazepines and barbituates, which are also allosteric modulators, can cause adverse effects because they bind to other receptors throughout the brain. CoCensys claims that its Epalons are recognized by a unique receptor that is distinct from those for benzodiazepines and barbituates and therefore show "a lower level of toxicity" and side effects. In preparation for moving the start-up into the clinical development phase, CoCensys recruited former Adria Labs North America President Daniel Korpolinski as president and CEO. Korpolinski, who also was with Upjohn for 24 years, succeeds company cofounder Robert McNeil, PhD, who moved to chairman. In other executive moves, former Sigma-Tau VP-Clinical Research Donald Ashbrook, PhD, has joined the firm as VP- scientific affairs. Kelvin Gee, PhD, another CoCensys cofounder, was promoted to chief scientific officer. Privately-held CoCensys, based in Irvine Calif., was founded in 1989 by Gee, McNeil, researchers at the University of Southern California School of Pharmacy and Fred Middleton of Sanderling Ventures. USC holds the domestic patents to the therapeutic uses of Epalon compounds, while CoCensys holds the international patents. CoCensys licenses the rights to Epalons from USC and currently has no other academic or corporate R&D affiliations. However, the company is looking to enter corporate partnerships. CoCensys has raised $ 3.7 mil. since its founding from venture capital firms including Sanderling, Domain Partners, U.S. Venture Partners, Abingworth Management Ltd., Biotechnology Investments Ltd. and Security Pacific Capital Corp.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel